PERSONALIZED CANCER TREATMENT
Geneov8 allows the early detection of gene mutations that puts your patient at a higher risk of developing a certain type of hereditary cancer, and provides an indication for relatives of possibly having the same gene mutation. At the same time, Geneov8 test gives more information to help the medical practitioner in implementing more proactive, personalized and actionable lifestyle intervention.
The test consists of 2 parts: First t analyses the most relevant genes for mutations that could increase risk for the following 8 hereditary cancers- Breast, Uterine, Melanoma, Stomach, Ovarian, Colorectal, Pancreatic, Prostate. Second part analyses the most relevant genes to optimize the individual’s nutrition, detoxification, and pharmacology to help minimize or prevent the downstream manifestation of the cancer.
RGCC screening tests determines the presence and concentration of circulating tumors. It also identifies the efficacy of specific drugs, natural biological extracts, and procedure or therapies on cancer cells for an individual. The tests are for specific functions: Screening and follow-up, Pharmacodynamics tests for Chemosensitivity/ Chemoresistance, Pharmacokinetics test for Chemosensitivity/Chemoresistance, and Immunology and Risk Assessment.
Screening and Follow-up Tools
Gives information on the presence and the concentration of Circulating Tumor Cells only. It only enumerates the progenitor cells that could cause potent relapse and recurrence of the disease.
Shows the presence of Circulating Tumor Cells, their concentration, and immunophenotype, which may help identify the cells’ origin.
This test is tailor-made for specific types of malignancies like breast cancer (Oncotrail R.G.C.C. for Breast), Prostate (Oncotrail R.G.C.C. for Prostate), Sarcoma, and the like. Since this test only includes markers relevant for a specific type of malignancy, the test is a good tool for follow up control.
Pharmacodynamics Tests Chemosensitivity/Chemoresistance
This test provides information on the efficacy of specific drugs on cancer cells from a single patient. This incorporates two procedures — epigenetic analysis and viability assays to validate the data.
This test shows the efficacy of natural biological substances or extracts on cancer cells. This is assessed using three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.
Along with the information provided by the Onconomics test, Onconomics Plus includes an examination of the efficacy of natural biological substances or extracts on cancer cells through three methods: the direct cytotoxic effect, stimulation of the immune system, and the inhibition of proliferative signals in the cancer cells.
Pharmacokinetics Tests Chemosensitivity/Chemoresistance
This test focuses on the effect of therapeutic agents against an individual patient’s cancer. ChemoSNip shows the ability of each patient to metabolize and activate the therapeutic agent to its effective form in a normal rate. This test includes all the therapeutic agents with anticancer activity.
Using specific cellular markers and cytokine production, Immune-frame detects the types of cells that are responsible for the activation or repression of the immune system of a patient. It uses two different assays: ELISA assay—used for the detection of cytokines from specific cells in serum sample; and flow cytometry for the enumeration of specific markers on peripheral blood cells.
This test is for finding out, based on CTC markers, whether and where the tumor is likely to metastasize — like in the lung, brain, liver, bones.